Orphan Disease Biotech Fate Therapeutics Files for a $69 Million IPO

Published: Aug 14, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Fate Therapeutics, a clinical-stage biotech developing stem cell treatments for orphan diseases, filed on Wednesday with the SEC to raise up to $69 million in an initial public offering. The San Diego, CA-based company, which was founded in 2007 and booked $2 million in grant and collaboration revenue for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol FATE.

Help employers find you! Check out all the jobs and post your resume.

Back to news